Iovance Biotherapeutics Stock Forecast, Price & News

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.02.
View Iovance Biotherapeutics' earnings history.

How has Iovance Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IOVA shares have decreased by 11.4% and is now trading at $26.20.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for IOVA?

12 brokerages have issued twelve-month price objectives for Iovance Biotherapeutics' stock. Their forecasts range from $18.00 to $51.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $39.00 in the next year. This suggests a possible upside of 48.9% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:

• Frederick G. Vogt, President, CEO, Secretary & General Counsel
• Igor P. Bilinsky, Chief Operating Officer
• Jean-Marc Bellemin, CFO & Principal Accounting Officer
• Friedrich Graf Finckenstein, Chief Medical Officer
• Sara Pellegrino, VP-Investor Relations & Public Relations

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include Novozymes A/S (NVZMY), argenx (ARGX), Repligen (RGEN), QIAGEN (QGEN), Novavax (NVAX), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).
View all of IOVA's competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.94%), Frontier Capital Management Co. LLC (0.44%), First Midwest Bank Trust Division (0.09%), Carnegie Capital Asset Management LLC (0.01%), Foundations Investment Advisors LLC (0.01%) and Stratos Wealth Partners LTD. (0.01%).
View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Midwest Bank Trust Division, Assenagon Asset Management S.A., Stratos Wealth Partners LTD., and Carnegie Capital Asset Management LLC.
View insider buying and selling activity for Iovance Biotherapeutics or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was purchased by a variety of institutional investors in the last quarter, including Foundations Investment Advisors LLC, and Berman Capital Advisors LLC.
View insider buying and selling activity for Iovance Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $26.20.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $4.06 billion. The biotechnology company earns $-259.58 million in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 241 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected].